Heart Failure With Preserved Ejection Fraction
Conditions
Brief summary
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Detailed description
This study will test whether Empagliflozin (Empa), with and without Potassium Nitrate (KNO3), improves submaximal exercise endurance, skeletal muscle oxidative phosphorylation capacity (SkM OxPhos), intramuscular perfusion, and changes in the skeletal muscle metabolome, proteome, and respiration in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Interventions
DRUGEmpagliflozin + Potassium Chloride
Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle. KCl is an active control.
DRUGEmpagliflozin + Potassium Nitrate
Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
DRUGPotassium Chloride + Placebo for Empagliflozin
Active control.
Sponsors
University of Pennsylvania
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All personnel will be masked except for the IDS pharmacist dispensing the drugs.
Intervention model description
3 interventions will be randomized and administered in a double-blind fashion
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion: 1\. NYHA Class II-III symptoms 2. Left ventricular ejection fraction \>= 50% 3. Stable medical condition for at least 2 weeks, as per investigator judgment 4. Prior or current evidence for elevated filling pressures, as evidenced by at least one of the following: a. Mitral early (E)/septal tissue annular (e') velocity ratio \> 8, in the context of a septal e' velocity \<=7 cm/s or a lateral e' \<= 10 cm/s, in addition to one of the following: i. Large left atrium (LA volume index \> 34 mL/m2) ii. Chronic loop diuretic use for control of symptoms iii. Elevated natriuretic peptides within the past year (e.g., NTproBNP \> 125 pg/mL in sinus rhythm or \> 375 pg/mL if in atrial fibrillation) b. Mitral E/e' ratio \> 14 at rest or during exercise c. Elevated invasively-determined filling pressures previously (resting left ventricular end-diastolic pressure \>= 16 mm Hg or pulmonary capillary wedge pressure \>= 15 mmHg; or PCWP/LVEDP \>= 25 mmHg with exercise) d. Prior episode of acute heart failure requiring IV diuretics
Exclusion criteria
1. Age \<18 years old 2. Pregnancy: Women of childbearing potential will undergo a urine pregnancy test during the screening visit. 3. Treatment with organic nitrates or phosphodiesterase inhibitors that cannot be interrupted 4. Uncontrolled atrial fibrillation, as defined by a resting atrial fibrillation heart rate \> 100 beats per minute at the time of the baseline assessment 5. Hemoglobin \< 10 g/dL 6. Subject inability/unwillingness to exercise 7. Moderate or greater left sided valvular disease (mitral regurgitation, aortic stenosis, aortic regurgitation), mild or greater mitral stenosis, severe right-sided valvular disease 8. Known hypertrophic, infiltrative, or inflammatory cardiomyopathy 9. Clinically significant pericardial disease, as per investigator judgment 10. Current angina due to clinically significant epicardial coronary disease, as per investigator judgment 11. Acute coronary syndrome or coronary intervention within the past 2 months 12. Primary pulmonary artery hypertension (WHO Group 1 Pulmonary Arterial Hypertension) 13. Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary Disease Stage III or greater GOLD criteria (FEV1\<50%), treatment with oral steroids within the past 6 months for an exacerbation of obstructive lung disease, current use of supplemental oxygen aside from nocturnal oxygen for the treatment of obstructive sleep apnea. \- Desaturation to \<90% on the baseline maximal effort cardiopulmonary exercise test will also be grounds for exclusion 14. Clinically-significant ischemia, as per investigator's judgement, on stress testing without either (1) subsequent revascularization, (2) an angiogram demonstrating the absence of clinically significant epicardial coronary artery disease, as per investigator judgment; (3) a follow-up 'negative' stress test, particularly when using a more specific technique (i.e., a negative perfusion imaging test following a 'positive' ECG stress test) \- Exercise-induced regional wall motion abnormalities on the echocardiographic assessment during the baseline maximal effort cardiopulmonary exercise test will also be exclusionary 15. Left ventricular ejection fraction \< 45% on a prior echocardiogram or cardiac MRI, unless the reduced LVEF occurred within the context of an uncontrolled supraventricular arrhythmia, with return of a normal ejection fraction following treatment of the arrhythmia 16. Significant liver disease impacting synthetic function or volume control (ALT/AST \> 3x ULN, Albumin \< 3.0 g/dL) 17. eGFR \< 30 mL/min/1.73m2. 18. Methemoglobin \> 5% 19. Serum potassium \> 5.0 mEq/L on baseline testing 20. Type I Diabetes 21. History of ketoacidosis 22. Current use of, or prior intolerance to, an SGLT2i 23. Ongoing maintenance of a 'Ketogenic Diet' (low carbohydrate, high fat) 24. Allergy to beets 25. Severe right ventricular dysfunction 26. Baseline resting seated systolic blood pressure \> 180 mmHg or \< 100 mmHg 27. Persistently low or high seated blood pressure or orthostatic blood pressure response to the transition from supine to standing (\>20 mmHg reduction in systolic blood pressure 2-3 minutes after standing, or a fall in SBP to \< 90 mmHg) at the baseline visit 28. Active participation in another study that utilizes an investigational agent (observational studies/registries allowed) 29. Any condition that, in the opinion of the investigator, may interfere with the completion/performance of the study. This may include comorbid or psychiatric conditions that may impede successful completion of the protocol, or logistical concerns (e.g., inability to travel to the exercise unit).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Submaximal Exercise Endurance | Week 6 | Time to exhaustion while exercising at 75% peak workload |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intramuscular Perfusion | Week 6 | MRI assessment of skeletal muscle perfusion |
| VO2 Kinetics | Week 6 | Assess the impact of interventions on the kinetics of oxygen consumption (VO2 kinetics) during exercise and recovery. "On" and "Off" kinetics will be modeled during the submaximal exercise transient. |
| VO2 Efficiency | Week 6 | Assess the impact of interventions on the efficiency of oxygen consumed above basal metabolic rate compared to total work performed |
| Vasodilatory Reserve | Week 6 | Percent change in systemic vascular resistance (SVR) at baseline vs SVR at 4 minutes of exercise at end of each intervention period |
| Venous Substrate Concentration | Week 6 | Change in venous substrate concentrations at time of fatigue at end of each intervention period |
| Respiratory Exchange Ratio | Week 6 | Change in RER at 4 minutes of exercise at end of each intervention period |
| KCCQ Overall Summary Score | Week 6 | Assess impact of interventions on quality of life based on Kansas City Cardiomyopathy Questionnaire overall summary score |
| Ambulatory Physical Activity | Week 6 | Use actigraphy to document the average steps per day taken during the final week of each interventional period |
| Muscle Tissue Respirometry | Week 6 | Measure tissue rates of substrate metabolism and mitochondrial content |
| Muscle Proteome | Week 6 | Measure relative abundances of proteins related to fatty acid and ketone oxidation as well as proteins related to mitochondrial biogenesis. |
| Muscle Metabolome | Week 6 | Perform targeted quantitative metabolomics to assess changes in substrate metabolism |
| Skeletal Muscle Oxidative Capacity | Week 6 | MRI assessment of skeletal muscle oxidative phosphorylation capacity |
| Arteriovenous O2 content difference | Week 6 | quotient of VO2 to cardiac output |
| Peak VO2 during Submaximal Exercise | Week 6 | Assess the impact of interventions on the peak oxygen consumption achieved during submaximal exercise |
Countries
United States
Contacts
CONTACTMelissa Fernando
CONTACTCassandra Demastus, CRNP
PRINCIPAL_INVESTIGATORPayman Zamani, MD
University of Pennsylvania
Outcome results
None listed